Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 545-549 , July 2009

In vitro human leukocyte labeling with 64Cu: an intraindividual comparison with 111In-oxine and 18F-FDG

  • Kuldeep K. Bhargava

      Affiliations

    • Division of Nuclear Medicine and Molecular Imaging, North Shore Long Island Jewish Health System, Manhasset and New Hyde Park, NY 11040, USA
    • ,
  • Raj K. Gupta

      Affiliations

    • Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    • ,
  • Kenneth J. Nichols

      Affiliations

    • Division of Nuclear Medicine and Molecular Imaging, North Shore Long Island Jewish Health System, Manhasset and New Hyde Park, NY 11040, USA
    • ,
  • Christopher J. Palestro

      Affiliations

    • Division of Nuclear Medicine and Molecular Imaging, North Shore Long Island Jewish Health System, Manhasset and New Hyde Park, NY 11040, USA
    • Corresponding Author InformationCorresponding author. Division of Nuclear Medicine and Molecular Imaging, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA. Tel.: +1 718 470 7081; fax: +1 718 831 1147.

Received 5 February 2009 ,Revised 26 February 2009 ,Accepted 1 March 2009.

References 

  1. Datz FL. Indium-111-labeled leukocytes for the detection of infection: current status. Semin Nucl Med. 1994;24:92–109
  2. Palestro CJ, Love C, Bhargava KK. Labeled leukocyte imaging: current status and future directions. Q J Nucl Med Mol Imaging. 2009;53:105–123
  3. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47–59
  4. Love C, Tomas MB, Tronco GG, Palestro CJ. Imaging infection and inflammation with 18F-FDG-PET. Radiographics. 2005;25:1357–1368
  5. Strobel K, Stumpe KD. PET/CT in musculoskeletal infection. Semin Musculoskelet Radiol. 2007;11:353–364
  6. Bleeker-Rovers CP, Vos FJ, Corstens FH, Oyen WJ. Imaging of infectious diseases using [18F] fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging. 2008;52:17–29
  7. Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-d-glucose as a potential in vitro agent for labeling human granulocytes for clinical studies by positron emission tomography. Nucl Med Biol. 1992;19:183–190
  8. Forstrom LA, Mullan BP, Hung JC, Lowe VJ, Thorson LM. 18F-FDG labeling of human leukocytes. Nucl Med Commun. 2000;21:691–694
  9. Forstrom LA, Dunn WL, Mullan BP, Hung JC, Lowe VJ, Thorson LM. Biodistribution and dosimetry of [18F]flurodeoxyglucose labeled leukocytes in normal human subjects. Nucl Med Commun. 2002;23:721–725
  10. Pio BS, Fergus RB, Aranda R, Boulay G, Spicher K, Song MH, et al. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-2[18F]fluoro-d-glucose-labeled white blood cells. Mol Imaging Biol. 2003;5:271–277
  11. Rini JN, Bhargava KK, Tronco GG, Singer C, Caprioli R, Marwin SE, et al. PET with FDG labeled autologous leukocytes versus scintigraphy 111In-oxine-labeled leukocytes for detection of infection. Radiology. 2006;238:978–987
  12. Dumarey N, Egrise D, Blocklet D, Stallenberg B, Remmelink M, del Marmol V, et al. Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med. 2006;47:625–632
  13. Pellegrino D, Bonab AA, Dragotakes SC, Pitman JT, Mariani G, Carter EA. Inflammation and infection: Imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med. 2005;46:1522–1530
  14. Rini JN, Palestro CJ. Imaging of infection and inflammation with 18F-FDG-labeled leukocytes. Q J Nucl Med Mol Imaging. 2006;50:143–146
  15. Philpott GW, Schwarg SW, Anderson CJ, Dehdashti F, Connett JM, Zinn KR, et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med. 1995;36:1818–1824
  16. Anderson CJ, Connett JM, Baumann ML, Schwarz SW, Zinn KR, Phillpott GW, et al. Comparison of Cu-67 and Cu-64 as potential radionuclides for radiotherapy. J Nucl Med. 1993;34:134P
  17. Thakur ML, Lavender JP, Arnot RN, Silvester DJ, Segal AW. Indium-111-labeled autologous leukocytes in man. J Nucl Med. 1977;18:1014–1021
  18. Danpure HJ, Osman S, Carroll MJ. The development of a clinical protocol for the radiolabelling of mixed leukocytes with 99Tcm-hexamethylpropyleneamine oxime. Nucl Med Commun. 1988;9:465–475
  19. McAfee JG, Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes II. J Nucl Med. 1976;17:488–492
  20. Knowles DM, Murray A, Chadburn A. Organization and operations of hematopathology laboratory. In:  Knowles DM editors. Neoplastic hematopathology. 2nd ed.. Baltimore: William and Wilkins; 2001;p. 419–466
  21. Burke JET, Roath S, Ackery D, Wyeth P. The comparison of 8-hydoxyquinoline, tropolone, and acetyl acetone as mediators in the labelling of polymorphonuclear leucocytes with indium-111: a functional study. Eur J Nucl Med. 1982;7:73–76
  22. Datz FFL, Bedont RA, Baker WJ, Alazraki NP, Taylor A. No difference in sensitivity for occult infection between tropolone- and oxine-labeled leukocytes. J Nucl Med. 1985;26:469–473
  23. Resnick LM, Gupta RK, Bhargava KK, Gruenspan H, Alderman MH, Laragh JH. Cellular ions in hypertension, diabetes and obesity. A nuclear magnetic resonance spectroscopic study. Hypertension. 1991;17:951–957
  24. Roddie ME, Peters AM, Danpure HJ, Osman S, Henderson BL, Lavender JP, et al. Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes. Radiology. 1988;166:767–772
  25. Robins PD, Salazar I, Forstrom LA, Mullan BP, Hung JC. Biodistribution and radiation dosimetry of stabilized 99mTc-exametazime labeled leukocytes in normal subjects. J Nucl Med. 2000;41:934–940

☆ This work was supported in part by NIH Grant #5RO1GM 071324-20.

PII: S0969-8051(09)00079-1

doi: 10.1016/j.nucmedbio.2009.03.001

Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 545-549 , July 2009

Article Tools

* Image Usage & Resolution